loading
Schlusskurs vom Vortag:
$1.40
Offen:
$1.42
24-Stunden-Volumen:
1.01M
Relative Volume:
0.42
Marktkapitalisierung:
$516.03M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.775
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
+0.00%
1M Leistung:
+6.77%
6M Leistung:
+101.88%
1J Leistung:
-22.83%
1-Tages-Spanne:
Value
$1.40
$1.46
1-Wochen-Bereich:
Value
$1.36
$1.53
52-Wochen-Spanne:
Value
$0.2836
$2.08

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Firmenname
Lexicon Pharmaceuticals Inc
Name
Telefon
(281) 863-3000
Name
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Mitarbeiter
103
Name
Twitter
@LexPharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
LXRX's Discussions on Twitter

Vergleichen Sie LXRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LXRX
Lexicon Pharmaceuticals Inc
1.42 508.76M 1.21M -177.12M -162.37M -0.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.39 108.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.43 60.82B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.95 61.02B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
817.32 50.01B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.81 34.05B 4.56B -176.77M 225.30M -1.7177

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-05 Herabstufung Leerink Partners Outperform → Market Perform
2024-06-17 Eingeleitet H.C. Wainwright Buy
2024-04-30 Eingeleitet Leerink Partners Outperform
2023-03-07 Eingeleitet Jefferies Hold
2022-08-12 Eingeleitet Piper Sandler Overweight
2021-01-29 Hochstufung JP Morgan Underweight → Neutral
2021-01-29 Herabstufung Wedbush Outperform → Neutral
2020-12-08 Hochstufung Citigroup Neutral → Buy
2020-11-18 Hochstufung Gabelli & Co Hold → Buy
2019-12-11 Herabstufung Gabelli & Co Buy → Hold
2019-11-08 Herabstufung Citigroup Buy → Neutral
2019-09-11 Hochstufung Gabelli & Co Hold → Buy
2019-07-29 Herabstufung Stifel Buy → Hold
2019-03-25 Hochstufung Gabelli & Co Sell → Hold
2018-07-31 Bestätigt Stifel Buy
2018-02-23 Herabstufung Needham Buy → Hold
2018-02-14 Herabstufung JP Morgan Neutral → Underweight
2017-03-01 Bestätigt H.C. Wainwright Buy
2017-03-01 Bestätigt Wedbush Outperform
2016-10-07 Eingeleitet H.C. Wainwright Buy
2016-08-05 Bestätigt Wedbush Outperform
2016-08-02 Eingeleitet Citigroup Buy
2016-03-02 Bestätigt Wedbush Outperform
2015-11-09 Bestätigt Wedbush Outperform
2015-09-28 Hochstufung Gabelli & Co Sell → Hold
2015-09-18 Herabstufung Gabelli & Co Hold → Sell
2015-08-10 Herabstufung JP Morgan Overweight → Neutral
Alle ansehen

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

pulisher
12:34 PM

Is Lexicon Pharmaceuticals Inc. stock attractive for growth ETFsJuly 2025 Institutional & Consistent Profit Alerts - newser.com

12:34 PM
pulisher
Oct 25, 2025

What candlestick patterns are forming on Lexicon Pharmaceuticals Inc.Market Sentiment Review & Free High Return Stock Watch Alerts - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsQuarterly Profit Summary & Weekly High Return Forecasts - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Using data tools to time your Lexicon Pharmaceuticals Inc. exitJuly 2025 Outlook & Technical Pattern Alert System - newser.com

Oct 25, 2025
pulisher
Oct 24, 2025

Published on: 2025-10-24 01:54:11 - newser.com

Oct 24, 2025
pulisher
Oct 21, 2025

Is Lexicon Pharmaceuticals Inc. building a consolidation baseDip Buying & Safe Swing Trade Setups - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 14:44:52 - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Full technical analysis of Lexicon Pharmaceuticals Inc. stockEntry Point & Safe Entry Zone Tips - newser.com

Oct 21, 2025
pulisher
Oct 19, 2025

What analysts say about Lexicon Pharmaceuticals Inc stockTrading Volume Trends & Double Or Triple Investment - earlytimes.in

Oct 19, 2025
pulisher
Oct 18, 2025

Macro Review: Is Lexicon Pharmaceuticals Inc. stock a defensive play in 20252025 Market Overview & Comprehensive Market Scan Reports - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

How analysts rate Lexicon Pharmaceuticals Inc. stock todayWeekly Trend Recap & Long-Term Growth Stock Strategies - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

Activity Recap: How analysts rate Lexicon Pharmaceuticals Inc. stock todayJuly 2025 EndofMonth & Community Trade Idea Sharing - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Is Lexicon Pharmaceuticals Inc. stock a defensive play in 20252025 Pullback Review & AI Optimized Trading Strategy Guides - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Lexicon Pharmaceuticals Inc Stock Analysis and ForecastSector Leadership Analysis & Affordable Growth Strategies - earlytimes.in

Oct 17, 2025
pulisher
Oct 14, 2025

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - The Manila Times

Oct 14, 2025
pulisher
Oct 14, 2025

Lexicon Pharmaceuticals Advances 10mg Pilavapadin to Phase 3 | LXRX Stock News - Stock Titan

Oct 14, 2025
pulisher
Oct 14, 2025

Short interest data insights for Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com

Oct 14, 2025
pulisher
Oct 10, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% HigherWhat's Next? - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3%Time to Sell? - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon (LXRX) Engages in Policy Discussion to Tackle Chronic Pa - GuruFocus

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People With Chronic Pain - 富途牛牛

Oct 08, 2025
pulisher
Oct 06, 2025

Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIEarnings Beat & Intraday High Probability Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Lexicon Pharmaceuticals Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Oct 04, 2025

Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$37.26
price up icon 1.11%
$91.28
price up icon 2.21%
$29.89
price up icon 0.07%
$105.66
price up icon 0.87%
$159.66
price down icon 0.29%
biotechnology ONC
$310.81
price up icon 0.25%
Kapitalisierung:     |  Volumen (24h):